

Tibulizumab

Catalogue No.:abx831453

Tibulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A/TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Target:	IL17A/TNFSF13B/CD257
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG4 Kappa-[scFv]2
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	1849636-24-3
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC,
	THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL
	CONSUMPTION.
v1.0.0	Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951 Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413 Abbexa BV, Leiden, NL Website: www.abbexa.com · Email: info@abbexa.com